This article has been updated with comments from a conference call following the release of the firm's financial results.

NEW YORK (GenomeWeb) – NeoGenomics reported today a nine percent increase in fourth quarter revenues on increased base test volume growth, helping the firm top Wall Street's consensus estimate.

For the three-month period ended Dec. 31, the cancer genetics testing firm reported revenues of $27.3 million compared to $25 million in the same period the year before. Analysts had, on average, expected revenues of $26.5 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.